References

American Academy of Pediatrics Section on Hematology/Oncology; American Academy of Pediatrics Section on Allergy/Immunology, Lubin BH, Shearer WT. Policy Statement: Cord blood banking for potential future transplantation. Pediatrics. 2007;119(1):165-170.

Arai S, Miklos DB. Rituximab in hematopoietic cell transplantation. Expert Opin Biol Ther. 2010 Apr 26.

Arfons LM, Tomblyn M, Rocha V, Lazarus HM. Second hematopoietic stem cell transplantation in myeloid malignancies. Curr Opin Hematol. 2009;16(2):112-23.

Bhatia S, Bhatia R. Transplantation-Related Malignancies. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 8th ed. Philadelphia, Pa: Wolters Kluwer/Lippincott Williams & Wilkins; 2008: 2417-2426.

Bishop MR, Pavletic SZ. Hematopoietic stem cell transplantation. In: Abeloff MD, Armitage JO, Niederhuber JE, et al. Abeloff’s Clinical Oncology, 4th ed. Philadelphia: Churchill Livingstone Elsevier; 2008: 501-512.

Brunstein CG, Weisdorf DJ. Future of cord blood for oncology uses. Bone Marrow Transplant. 2009;44(10):699-707.

Centers for Disease Control, National Center for Infectious Diseases. Epstein Barr Virus and Infectious Mononucleosis. Accessed at www.cdc.gov/ncidod/diseases/ebv.htm on May 6, 2011.

Champlin R. Hematopoietic cellular transplantation. In: Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF, Frei E, eds. Cancer Medicine. 6th ed. Hamilton, Ontario:BC, Decker Inc.; 2003:1019-1036.

Childs RW. Allogeneic hematopoietic stem cell transplantation. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 8th ed. Philadelphia, Pa: Wolters Kluwer/Lippincott Williams & Wilkins; 2008:2548-2568.

Cutler C, Ballen K. Reduced-intensity conditioning and umbilical cord blood transplantation in adults. Bone Marrow Transplant. 2009;44(10):667-71.

Delaney C, Ratajczak MZ, Laughlin MJ. Strategies to enhance umbilical cord blood stem cell engraftment in adult patients. Expert Rev Hematol. 2010;3(3):273-283.

Druker BJ, Lee SJ. Chronic Myelogenous Leukemia. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 8th ed. Philadelphia, Pa: Wolters Kluwer/Lippincott Williams & Wilkins; 2008:2267-2278.

Gallagher G, Forrest DL. Second Solid Cancers After Allogeneic Hematopoietic Stem Cell Transplantation. Cancer. 2007;109:84-92.

Gallardo D, de la Cámara R, Nieto JB, Espigado I, et al. Is mobilized peripheral blood comparable with bone marrow as a source of hematopoietic stem cells for allogeneic transplantation from HLA-identical sibling donors? A case-control study. Haematologica. 2009;94(9):1282-8.

Harper JL, Corbacioglu S. Veno-occlusive Hepatic Disease, 6/22/10. Accessed at http://emedicine.medscape.com/article/989167-overview on May 6, 2011.

Hede K. Half-Match Bone Marrow Transplants May Raise Odds for More Recipients. J Natl Cancer Inst. 2011;103(10):781-783.

Kumar A, Kharfan-Dabaja MA, Glasmacher A, Djulbegovic B. Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. J Natl Cancer Inst. 2009;101(2):100-6.

Ludajic K, Balavarca Y, Bickeböller H, Minor ABO-mismatches are risk factors for acute graft-versus-host disease in hematopoietic stem cell transplant patients. Biol Blood Marrow Transplant. 2009;15(11):1400-1406.

Mineishi S, Ferrara JLM. Autologous stem cell transplantation. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 8th ed. Philadelphia, Pa: Wolters Kluwer/Lippincott Williams & Wilkins; 2008:2541-2548.

National Cancer Institute. Bone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation. Accessed at www.cancer.gov/cancertopics/factsheet/Therapy/bone-marrow-transplant on May 6, 2011.

National Comprehensive Cancer Center Network. NCCN Guidelines for Cancer Care by Site. Accessed at www.nccn.org/professionals/physician_gls/f_guidelines.asp on May 5, 2011

National Marrow Donor Program. Accessed at www.marrow.org/ on May 6, 2011.

Samavedi V, Sacher RA. Hematapoietic Stem Cell Transplantation. December 2010. Accessed at http://emedicine.medscape.com/article/208954-overview on May 11, 2011,

Socie G, Salooja N, Cohen A, et.al. Nonmalignant late effects after allogeneic stem cell transplantation. Blood. 2003;101:3373-3385.

Sundin M, Le Blanc K, Ringden O, et.al. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation. Haematologica/The Hematology Journal. 2006;91:1059-1067.

Vargo MM, Smith RG, Stubblefield MD. Rehabilitation of the Cancer Patient. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 8th ed. Philadelphia, Pa: Wolters Kluwer/Lippincott Williams & Wilkins; 2008:2857-2883.

Weisdorf DJ, Nelson G, Lee SJ, et al; Chronic Leukemia Working Committee. Sibling versus unrelated donor allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia: refined HLA matching reveals more graft-versus-host disease but not less relapse. Biol Blood Marrow Transplant. 2009;15(11):1475-8.

Williams KM, Chien JW, Gladwin MT, Pavletic SZ. Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. JAMA. 2009;302(3):306-14.

Zamkoff KW, Bergman S, Beaty MW, et. al. Fatal EBV-related post-transplant lymphoproliferative disorder (LPD) after matched related donor nonmyeloablative peripheral blood progenitor cell transplant. Bone Marrow Transplantation. 2003;31:219-222.